Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

17.14
BATS BZX Real-Time Price
As of 12:49pm ET
 +0.10 / +0.59%
Today’s Change
16.73
Today|||52-Week Range
53.96
-52.72%
Year-to-Date
TEVA Regular Dividend: TEVA will begin trading ex-dividend on 08/25/17 with a $0.085 dividend payable to shareholders of record as of 08/29/17.
Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why
Aug 21 / Zacks.com - Paid Partner Content
The Market Is Not About Washington: Cramer's 'Mad Money' Recap (Wed 8/16/17)
Aug 16 / TheStreet.com - Paid Partner Content
Oversold Small-Cap Biotech Names
Aug 18 / TheStreet.com - Paid Partner Content
Teva Stock Tumbles Again, Citi Downgrades, Says 'We Have Been Wrong'
Aug 16 / TheStreet.com - Paid Partner Content
Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain
Aug 17 / TheStreet.com - Paid Partner Content
Teva Blood Is in the Streets
Aug 16 / GuruFocus News - Paid Partner Content
PayPal, Marriott International, Randgold Resources: 'Mad Money' Lightning Round
Aug 16 / TheStreet.com - Paid Partner Content
Teva Is Cheap, Not Dead
Aug 16 / TheStreet.com - Paid Partner Content
Valeant Pharmaceuticals: Cramer's Top Takeaways
Aug 16 / TheStreet.com - Paid Partner Content
International Paper, Inogen, Teva Pharmaceuticals: 'Mad Money' Lightning Round
Aug 15 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close17.04
Today’s open17.11
Day’s range16.73 - 17.47
Volume553,252
Average volume (3 months)12,786,231
Market cap$17.3B
Dividend yield6.45%
Data as of 12:49pm ET, 08/22/2017

Growth & Valuation

Earnings growth (last year)-96.18%
Earnings growth (this year)-15.48%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+12.01%
P/E ratioNM
Price/Sales1.59
Price/Book0.58

Competitors

 Today’s
change
Today’s
% change
BGNEBeiGene Ltd+1.74+2.60%
TYMETyme Technologies In...-0.05-0.85%
OASMOasmia Pharmaceutica...+0.01+0.98%
Data as of 12:34pm ET, 08/22/2017

Financials

Next reporting dateNovember 2, 2017
EPS forecast (this quarter)$1.10
Annual revenue (last year)$22.0B
Annual profit (last year)$330.0M
Net profit margin1.50%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President &
Chief Executive Officer
Yitzhak Peterburg
President &
CEO-Global Operations
Carlo de Notaristefani
Corporate headquarters
Petach Tikva, Hamerkaz

Forecasts